For optimal viewing of the AACI Update click here.
News from the Association of American Cancer InstitutesSeptember 2015
The Association is dedicated to reducing the burden of cancer by enhancing the impact of the nation's leading academic cancer centers.
AACI Update is an e-newsletter for the cancer center directors and key contacts at AACI member institutions and individuals interested in the cancer center-related activities of AACI. AACI Update reports on the progress of AACI initiatives and other AACI endeavors that benefit the cancer community and highlights important news and events at AACI member institutions.

AACI encourages member institutions to submit cancer center highlights to AACI Update. News briefs are linked to complete stories posted on individual cancer center websites. Please e-mail materials to aaciupdate@aaci-cancer.org. AACI reserves the right to decide whether or not materials are appropriate for inclusion.

To subscribe to AACI Update, please send an e-mail to aaciupdate@aaci-cancer.org with your name, title, address, and telephone number asking to be added to the AACI's distribution list.

To unsubscribe from AACI Update, please send an e-mail to aaciupdate@aaci-cancer.org with your name, title, and unsubscribe in the subject line to be removed from AACI's distribution list.


Mailing address:
3708 Fifth Avenue
Medical Arts Building, 503
Pittsburgh, PA 15213

Headlines

DiPaola, Gruber, Johnson Tapped for AACI Board

AACI congratulates Robert S. DiPaola, MD, Stephen B. Gruber, MD, PhD, MPH, and Candace S. Johnson, PhD, on their election to the AACI Board of Directors. The directors' three-year terms will start on October 25, during the AACI/CCAF annual meeting in Washington, DC. more...

Tisch Earns NCI Designation, Four AACI Centers Named Comprehensive
Congratulations to Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, the first new center to be added to the National Cancer Institute's cancer centers program in two years. Four other AACI-member cancer centers have earned comprehensive status: Dan L. Duncan Cancer Center at Baylor College of Medicine; Harold C. Simmons Cancer Center at UTSW Medical Center; Huntsman Cancer Institute at the University of Utah; and, University of New Mexico Cancer Center. more...

Roberts Named New Director at St. Jude
St. Jude Children's Research Hospital has named Charles W. M. Roberts, MD, PhD, as executive vice president and director of the St. Jude Comprehensive Cancer Center, the first and only National Cancer Institute (NCI)-designated Comprehensive Cancer Center devoted solely to children. Dr. Roberts will also serve as full member in the Department of Oncology and hold the Lillian R. Cannon Comprehensive Cancer Center Director Endowed Chair. more...

New York Times Well Columnist Suleika Jaouad to Open Annual Meeting
At age 22, shortly after her graduation from Princeton University, Suleika Jaouad was diagnosed with myelodysplastic syndrome and acute myeloid leukemia. Her New York Times Well column, "Life Interrupted", chronicles her journey as a young woman living with cancer. Ms. Jaouad will share her story in the opening keynote presentation at the annual meeting of the Association of American Cancer Institutes (AACI), October 25-27, at the Mandarin Oriental, in Washington, DC.

Susan Dentzer will be the moderator for Ms. Jaouad's talk at 1:15 PM Sunday, October 25. Ms. Dentzer is a Senior Policy Adviser to the Robert Wood Johnson Foundation, an on-air analyst on health issues with the PBS NewsHour and a regular commentator on health policy for National Public Radio, Al Jazeera America and other television and radio networks. more...


Recap: 7th Annual AACI CRI Meeting

The Association of American Cancer Institutes (AACI) Clinical Research Initiative (CRI) convened its seventh annual meeting, July 8-9, in Chicago. The 2015 meeting covered two full days and was attended by more than 200 clinical research office leaders, medical directors and cancer center administration.

The AACI CRI annual meeting is designed to improve the clinical research process, understand the global impact of conducting clinical research in the United States and abroad, discuss trends in clinical trials safety and compliance and recommend polices to promote staff retention at the cancer centers. more...
News from the Centers
Awards & Honors
Testa Appointed Senior Editor for Cancer Research
Fox Chase Cancer Center, Temple Health
Joseph R. Testa, PhD, professor and Carol and Kenneth E. Weg Chair of Human Genetics at Fox Chase Cancer Center, has been appointed to serve as senior editor for Cancer Research, a journal of the American Association for Cancer Research. Dr. Testa specializes in cancer genetics, specifically AKT and mesothelioma, at Fox Chase. He will serve as editor of the molecular and cellular pathobiology section of the journal for a three-year term. more...
Physician, Researcher Named Next President of the National Medical Association
Sidney Kimmel Cancer Center at Thomas Jefferson University
Edith Mitchell, MD, Professor of Medical Oncology at Thomas Jefferson University, was appointed president of the National Medical Association (NMA) at the NMA's 113th Annual Convention and Scientific Assembly in Detroit. The NMA is the nation's oldest and largest professional society for African American physicians, with more than 30,000 members. more...
Simeone Named Upcoming Chair of Pancreatic Cancer Action Network Scientific Board
University of Michigan Comprehensive Cancer Center
Diane Simeone, MD, director of the Pancreatic Cancer Center at the University of Michigan, was recently named the upcoming chair of the National Scientific and Medical Advisory Board for the Pancreatic Cancer Action Network. Her two-year term as chair runs from 2017 to 2019. Dr. Simeone will serve as chair-elect until then. more...
Chasing the Invisible Trail of Targeting Triple-Negative Breast Cancer
University of Kansas Cancer Center
Priyanka Sharma, MD, was awarded the 2015 Advanced Clinical Research Award in Breast Cancer from the American Society of Clinical Oncology to continue her research on triple-negative breast cancer. Dr. Sharma is looking at what she's calling "BRCAness" or deficiency in DNA damage repair machinery (specifically homologous recombination repair pathway defects) in triple-negative breast cancer as a potential prognostic and predictive marker. more...
Morrison Joins Federal Panel on Diagnostic Testing
Roswell Park Cancer Institute
Carl Morrison, MD, DVM, has been appointed to the federal Advisory Panel on Clinical Diagnostic Laboratory Tests. The new 15-member panel has been established by the Centers for Medicare & Medicaid Services (CMS), a division of the U.S. Department of Health and Human Services, to help guide and inform CMS leadership on decisions and policies regarding new diagnostic laboratory tests. more...
Grants & Gifts
Siteman Earns Highest Rating from NCI​​​​​​​​​
Siteman Cancer Center
The National Cancer Institute (NCI) has awarded Siteman Cancer Center​ at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis an "exceptional" rating, based on a rigorous review of Siteman's research programs. Siteman earned its exceptional rating based on a January site visit by 26 researchers and administrators from academic cancer centers across the United States. Timothy Eberlein​, MD, is the center's director. more...
NCI Renews Comprehensive Cancer Center Grant for $25.6 Million
University of Pittsburgh Cancer Institute
The University of Pittsburgh Cancer Institute (UPCI) has been rated "outstanding" and renewed as a National Cancer Institute (NCI)-designated Comprehensive Cancer Center. The five-year grant is for $25.6 million and comes as UPCI celebrates its 30th year working to reduce the burden of cancer. more...
$11 Million Received from NCI for Lung Cancer Research
Yale Cancer Center
Armed with an $11 million grant from the National Cancer Institute (NCI), Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven will launch a new research program in non-small cell lung cancer. Roy S. Herbst, MD, PhD, is principal investigator. The Specialized Program of Research Excellence, or SPORE, harnesses the strengths of academic cancer centers by bringing together experts in oncology, immunobiology, pharmacology, molecular biology, pathology, epidemiology, and addiction science to collaborate on projects. more...
$11 Million NCI Award to Accelerate Prostate Cancer Research
The Robert H. Lurie Comprehensive Cancer Center
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University has been awarded a new $11 million, five-year competitive grant from the National Cancer Institute (NCI) for its continued leadership of a Specialized Programs of Research Excellence (SPORE) in prostate cancer; one of only eight in the country. William Catalona, MD, is principal investigator of the Prostate SPORE. more...
Lerman Receives NCI Outstanding Investigator Award
Abramson Cancer Center of the University of Pennsylvania
Caryn Lerman, PhD, the senior deputy director of Penn's Abramson Cancer Center, has received the National Cancer Institute (NCI) Outstanding Investigator Award, a new grant bestowed upon influential cancer researchers to provide long-term support for their impactful and exceptional cancer research. Dr. Lerman, whose research focuses on the interface between neuroscience and cancer prevention, will receive $6.5 million over a seven-year period. more...
Kensler Awarded $6.3 Million for Studying How Food Can Lower Cancer Risks
University of Pittsburgh Cancer Institute
Thomas Kensler, PhD, professor of pharmacology and chemical biology and co-leader for the Cancer Epidemiology and Prevention Program at the University of Pittsburgh Cancer Institute, was awarded a $6.3 million Outstanding Investigator Award from the National Cancer Institute. This new award acknowledges experienced researchers and provides them with long-term support for their exceptional work. Dr. Kensler's research focuses on chemoprevention, or how food can be used to lower the risk of developing cancer caused by unavoidable environmental toxins. more...
Kwatra Receives NIH/NCATS Award
Duke Cancer Institute
In July the National Center for Advancing Translational Sciences (NCATS) announced nearly $3 million to fund cooperative agreements with four academic research groups to conduct pre-clinical validation studies, clinical feasibility studies or proof-of-concept clinical trials to test whether the selected assets may be effective against a previously unexplored disease target. Disease areas include glioblastoma. Madan M. Kwatra, PhD, associate professor of Pharmacology & Cancer Biology, has been awarded an NIH/NCATS grant to develop AZD9291 for glioblastoma. more...
Researcher Lands Grant to Study Link Between Obesity and Cancer
UK Markey Cancer Center
The National Cancer Institute recently awarded a $750,000 grant to University of Kentucky researcher Fredrick Onono, PhD, to study the potential link between obesity and breast cancer. Obese women are four times more likely to develop treatment-resistant breast cancer, but the exact mechanism for this observation is still largely a mystery. The link between high-fat diets and cancer development provides a clue that fats themselves may somehow be responsible for causing cells to malfunction. more...
Leadership Transitions
Hutch's COO and Executive Vice President Announces Retirement
Fred Hutchinson Cancer Research Center
In 1989, Myra Tanita walked through the doors of Fred Hutchinson Cancer Research Center for an interview for an internship she didn't think she really wanted. She changed her mind. And then, she stayed. Now, Tanita has announced her retirement from her 26-year career at the Hutch, where she has served as executive vice president and COO since 2003. more...
Rathmell to Direct Division of Hematology and Oncology
Vanderbilt-Ingram Cancer Center
W. Kimryn Rathmell, MD, PhD, has been named director of Vanderbilt's Division of Hematology and Oncology. Dr. Rathmell is a physician-scientist whose research focuses on the genetic and molecular signals that drive renal cell carcinomas (kidney cancers), and who specializes in the treatment of patients with rare and complex kidney cancers as well as prostate, bladder and testicular cancer. more...
Cristofanilli Appointed Associate Director for Precision Medicine and Translational Research
The Robert H. Lurie Comprehensive Cancer Center
Breast cancer expert Massimo Cristofanilli, MD, has been appointed Associate Director for Precision Medicine and Translational Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Director of Northwestern Onco-SET. Dr. Cristofanilli will join Northwestern Medicine in September 2015 as Professor of Medicine in the Division of Hematology-Oncology at Northwestern University Feinberg School of Medicine. more...
Physician-Scientist Named Head of Neuro-Oncology
Laura and Isaac Perlmutter Cancer Center at NYU Langone
NYU Langone Medical Center has announced the appointment of physician-scientist and brain tumor specialist Andrew S. Chi, MD, PhD, as the new chief of neuro-oncology for its Laura and Isaac Perlmutter Cancer Center and co-director of the NYU Langone Brain Tumor Center. more...
Childhood Cancer Expert to Chair Pediatrics at the University of Chicago
The University of Chicago Medicine Comprehensive Cancer Center
After a national search, John M. Cunningham, MD, the Donald N. Pritzker Professor and interim chair of the Department of Pediatrics at the University of Chicago, has been formally appointed chairman of the department, effective August 1. An authority on the study and treatment of childhood cancers, as well as the biology and therapy of hemoglobinopathies, Dr. Cunningham is known for his work on understanding the molecular mechanism underpinning red blood cell production. more...
Travis Leads Survivorship Research Efforts
Melvin and Bren Simon Cancer Center, Indiana University
An expert on cancer survivorship will lead the development of a new research program at the Indiana University Melvin and Bren Simon Cancer Center. Lois B. Travis, MD, ScD, has been named the Lawrence H. Einhorn Professor of Cancer Research at the IU School of Medicine and director of the Cancer Survivorship Research Program at the IU Simon Cancer Center. She is also a member of the cancer center's Cancer Prevention and Control research program, which focuses on prevention, early detection and survivorship. more...
New Hematology/Oncology Director Plans to Expand Clinical Services, Research
Hollings Cancer Center
Carolyn D. Britten, MD, an expert in Phase I cancer clinical trials, has been named director of the Hematology/Oncology Division in the Department of Medicine. Dr. Britten, the Charles Westfield Coker Endowed Chair in Gastrointestinal Oncology, also will continue to serve in her current role as associate director for clinical investigations at Hollings Cancer Center. more...
Research Highlights
Drinking Coffee Daily may Improve Survival in Colon Cancer Patients
Dana-Farber Cancer Institute
Regular consumption of caffeinated coffee may help prevent the return of colon cancer after treatment and improve the chances of a cure, according to a new, large study from Dana-Farber Cancer Institute. The patients, all of them treated with surgery and chemotherapy for stage III colon cancer, had the greatest benefit from consuming four or more cups of coffee a day. Two to three cups of coffee daily had a more modest benefit, while little protection was associated with one cup or less, reported the researchers, led by Charles S. Fuchs, MD, MPH. more...
Survivors of Childhood Cancer Have High-Risk of Recurrent Stroke
UCSF Helen Diller Family Comprehensive Cancer Center
Recent evidence suggests that survivors of childhood cancer have a high risk of suffering a stroke at a surprisingly young age. A new study from UC San Francisco’s Pediatric Brain Center shows that childhood cancer survivors suffering one stroke have double the risk of suffering a second stroke, when compared with non-cancer stroke survivors. The study found that the main predictors of recurrent stroke were cranial radiation therapy, hypertension and older age at first stroke - factors that could help physicians identify high-risk patients. more...
New Approach to Decades-Old Treatment Boosts Survival for Some Prostate Cancer Patients
Rutgers Cancer Institute of New Jersey
For more than 60 years, the standard of care for patients with prostate cancer fueled by androgen hormones that has spread to other parts of the body has been androgen deprivation therapy (ADT). While the response rate is high, resistance to ADT often occurs. Research coordinated by the ECOG-ACRIN Cancer Research Group, supported in part by the National Cancer Institute, examined the outcomes of giving the chemotherapy drug docetaxel at the start of ADT. The study's senior author, Robert S. DiPaola, MD, director of Rutgers Cancer Institute of New Jersey, helped lead the design of the protocol a decade ago when he was the national chairman of the ECOG Genitourinary Committee. more...
Linchpin Molecule for the Spread of Cancer Found
Sidney Kimmel Cancer Center at Thomas Jefferson University
For the first time, researchers at Thomas Jefferson University in Philadelphia report a single molecule that appears to be the central regulator driving metastasis in prostate cancer. Karen Knudsen, PhD, director of the Sidney Kimmel Cancer Center at Thomas Jefferson University, and colleagues have shown that one molecule appears to be central to many of the processes required for a cancer to spread. more...
Manipulating a Single Gene Turns Colorectal Cancer Cells Back to Normal
Memorial Sloan Kettering Cancer Center
Working in mice, Memorial Sloan Kettering scientists have found that genetic alterations in the APC gene, which are found in more than 90 percent of colorectal cancers, play an important role in driving the disease. The researchers are now asking whether potential drugs designed to undo the effects of these mutations could offer a future strategy to control colorectal cancer. more...
Novel Therapeutic Agent for Pediatric Cancer Developed
UC San Diego Moores Cancer Center
Donald L. Durden, MD, PhD, pediatric researcher at University of California, San Diego School of Medicine and Moores Cancer Center, has identified and developed a novel therapeutic target for neuroblastoma, the second most common solid-tumor childhood cancer. The agent, named SF1126, acts by inhibiting the part of the cancer cell engine that promotes tumor angiogenesis and growth. more...
Combination Therapy May be More Effective Against Most Common Ovarian Cancer
Jonsson Comprehensive Cancer Center, UCLA
High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but why it so frequently comes back after treatment has been a medical mystery. Now a team of UCLA researchers has discovered that a subset of tumor cells that don't produce the protein CA125, a biomarker used to test for ovarian cancer, has an enhanced ability to repair their DNA and resist programmed cell death - which allows the cells to evade the drug and live long enough to regrow the original tumor. more...
New Nanoparticle May Hold Key To Improved Treatments
Duke Cancer Institute
Researchers within the Pratt School of Engineering and the Duke Cancer Institute have designed a new nanoparticle-molecules tiny even by microscopic standards-that may offer the key to improved treatments for a variety of cancers. Ashutosh Chilkoti, PhD, professor of Biomedical Engineering, and other Duke faculty in the Medical School and DCI, found that their nanoparticles beat the current "gold standard" molecule used to deliver treatment for breast and prostate cancer. more...
Cancer’s Spread from Pancreas Stems from Interactions of Multiple Types of Wayward Cells
Abramson Cancer Center of the University of Pennsylvania
Tumor cells associated with pancreatic cancer often behave like communities by working with each other to increase tumor spread and growth to different organs. Groups of these cancer cells are better than single cancer cells in driving tumor spread, according to new research from the University of Pennsylvania and its Abramson Family Cancer Research Institute. more...
Potential Achilles' Heel for Prostate Cancer and B Cell Lymphoma Found
Memorial Sloan Kettering Cancer Center
In a recent study, Andrea Ventura, MD, PhD, and collaborators have shown that two types of cancer - B cell lymphoma and prostate cancer - depend on a particular microRNA, miR-19, in order to thrive. In mouse experiments, the researchers showed that removing miR-19 made the animals strikingly resistant to these cancers. Perhaps more importantly, the mice lacking miR-19 otherwise seemed largely normal, suggesting that drugs targeting it would carry little or no serious side effects. more...
Novel Model Developed to Predict Nicotine Emitted from E-Cigarettes
VCU Massey Cancer Center
Virginia Commonwealth University Massey Cancer Center researchers at the VCU Center for the Study of Tobacco Products (CSTP) have developed the first ever, evidence-based model that can predict with up to 90 percent accuracy the amount of nicotine emitted by an electronic cigarette (e-cigarette). Thomas Eissenberg, PhD, is director of the CSTP. more...
Pilot Clinical Trial Will Assess AGS-003 Immunotherapy in Kidney Cancer
Roswell Park Cancer Institute
Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of immunotherapies for the treatment of cancer based on the Arcelis technology platform, has announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy, or treatment to shrink a tumor before surgery, in patients with localized renal-cell carcinoma. The study is being conducted at Roswell Park Cancer Institute and is designed to enroll a maximum of 10 patients who will be treated with AGS-003 before nephrectomy in order to assess immune-system response and tumor effects. more...
Research Yields Possible New Cancer Therapy
University of Mississippi Medical Center Cancer Institute
Wael ElShamy, PhD, director of the University of Mississippi Medical Center Cancer Institute's Molecular Cancer Therapeutics Program, recently received a patent on a method to diagnose and treat several cancer types and subtypes. The method may lead to the first targeted therapy for triple negative breast cancer and add to therapies for other cancers. more...
Moffitt Teams with MD Anderson to Discover, Test Novel Agents to Prevent Cancer
Moffitt Cancer Center
Moffitt Cancer Center has joined MD Anderson's National Cancer Institute (NCI) Phase 0/I/II Cancer Prevention Clinical Chemoprevention Trials Consortia. Sponsored by the NCI's Division of Cancer Prevention, the consortia conducts early clinical development of promising new preventive agents through its Phase 0/I/II Cancer Prevention Clinical Trials Program. more...
Fertility Concerns Affect Breast Cancer Treatment Decisions
University of Michigan Comprehensive Cancer Center
Concerns about fertility kept a third of young women with breast cancer from taking tamoxifen, despite its known benefit in reducing the risk of breast cancer coming back, according to a study from the University of Michigan Comprehensive Cancer Center. In addition, the study found fertility concerns led a quarter of women who started tamoxifen to stop taking it before the recommended treatment period ended. more...
CanDL Database Shines Light on Clinically Important Cancer Gene Mutations
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital & Solove Research Institute

To help molecular pathologists, laboratory directors, bioinformaticians and oncologists identify key mutations that drive tumor growth in tissues obtained during clinical studies, researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) have designed an online database called the Cancer Driver Log, or CanDL. more...
Strange Circular DNA May Offer Way to Detect Cancers
University of Virginia Cancer Center
Strange rings of DNA that exist outside chromosomes are distinct to the cell types that mistakenly produced them, researchers have discovered. The finding raises the tantalizing possibility that the rings could be used as an indicator of different types of cancer. MicroDNAs were first discovered by a team of researchers at the University of Virginia School of Medicine. Following up on that discovery, the researchers have established that microDNAs are lineage-specific: Different cell types, such as prostate cancer cells or ovarian cancer cells, produce microDNAs that are unique to that cell type. more...
Tool Boosts Accuracy in Assessing Breast Cancer Risk
UCSF Helen Diller Family Comprehensive Cancer Center
A national risk model that gauges a woman's chance of developing breast cancer has been refined to give a more accurate assessment. The revised figures, based on data from more than one million patients, reveal a 300 percent increase in a subset of women whose five-year risk is estimated at 3 percent or higher. In a study published in the Journal of Clinical Oncology, researchers updated their current breast cancer risk model, which includes density categories - an important factor in determining the possibility of developing the disease - to one that also includes benign biopsy results. more...
Non-Hispanic Black Women Less Likely to Survive Endometrial Cancer Than Women of Other Races, Ethnicities
Barbara Ann Karmanos Cancer Institute
Non-Hispanic black women with endometrial cancer had worse outcomes than women in other racial/ethnic groups diagnosed with the same subtype of endometrial cancer and at the same stage of disease, according to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention. Michele L. Cote, PhD, and colleagues analyzed endometrial cancer incidence and mortality data from the Surveillance, Epidemiology, End Results database, including only the 120,513 cases diagnosed from 2000 to 2011. more...
Study Uses Computer Simulation to Model Patient Cancer DNA
UF Health Cancer Center
University of Florida Health researchers have launched a clinical trial that tests a new method of translating thousands of gene mutations into treatment options for patients. Using computer simulation modeling, the researchers will examine if the computer program will accurately predict how a person reacts to the different cancer therapies that their doctor has prescribed, depending on the person's genes. Not only will the software take the genes of a patient's cancer into account, it will also examine the genes that govern how a person reacts to a particular medication. more...
Relapse, Poor Survival in Acute Leukemia Linked to Genetic Mutations That Persist in Remission
Siteman Cancer Center
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations - detected after initial treatment with chemotherapy - are associated with an increased risk of relapse and poor survival. Using genetic profiling to study bone marrow samples from patients with acute myeloid leukemia, researchers found that those whose cells still carried mutations 30 days after the initiation of chemotherapy were about three times more likely to relapse and die than patients whose bone marrow was cleared of these mutations. Timothy J. Ley, MD, was senior author of the study. more...
Other News
ORIEN Adds Three Institutions to Growing Precision Cancer Research Collaboration
Moffitt Cancer Center
Amid greater recognition of the role of "big data" and data sharing in advancing cancer research, the Oncology Research Information Exchange Network (ORIEN) has announced three new members, bringing the total to nine. The unique research partnership among North America's top cancer centers, anchored by Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, has added Rutgers Cancer Institute of New Jersey, Morehouse School of Medicine and the University of Southern California Norris Comprehensive Cancer Center. more...
Pediatric Cancer Specialist Passes Away
The University of Chicago Medicine Comprehensive Cancer Center
Charles M. Rubin, MD, associate professor of pediatrics at the University of Chicago Medicine, a highly respected specialist in the care of children with cancer and a role model for medical students, residents and even established physicians, died while at work on Friday, July 17. He was 62. more...
Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research
Mount Sinai Health System Tisch Cancer Institute
The Mount Sinai Health System will work with Columbia Care LLC, a provider of medical marijuana, on research projects that evaluate the potential of related, experimental treatments. The collaboration moves into the next phase with the recent decision by the New York State Department of Health to award Columbia Care one of five state licenses to produce and dispense medical marijuana. Mount Sinai and Columbia Care are already cooperating on analyses of the company's patient registry data, with the goal to generate evidence about whether or not medical marijuana can help cancer patients regain lost weight or reduce nerve pain in HIV patients. more...
Research Organizations to Host International Cancer Immunotherapy Conference
American Association for Cancer Research (AACR)
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research (AACR) will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept. 16-19, 2015. Titled "Translating Science Into Survival," the meeting will cover all areas of inquiry in cancer immunology and immunotherapy. more...
UC San Diego, GSK Collaborate to Eradicate Cancer Stem Cells, Treat Leukemia
UC San Diego Moores Cancer Center
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center are working with GSK on a bench-to-bedside project to treat leukemia and other diseases by eliminating cancer stem cells. The collaboration is part of GSK's Discovery Partnerships with Academia (DPAc) program, where academic partners become core members of drug-hunting teams. Catriona Jamieson, MD, PhD, will lead UC San Diego's effort in the new DPAc team. more...
Job Opportunities
Associate Director of Development  
University of Hawai'i Cancer Center

more...

Endowed Chair in Cancer Innovation  
Winship Cancer Institute at Emory University

more...

Senior Director - Clinical Research  
Moffitt Cancer Center

more...

Core Facility Manager  
Moffitt Cancer Center

more...

Instructor - Genetics/Research  
Louisiana State University Health Sciences Center

more...

Assistant Professor - Genetics/Research  
Louisiana State University Health Sciences Center

more...

Regulatory Manager  
UNC Lineberger Comprehensive Cancer Center

more...

Director of Oncology Operations  
University of Maryland Medical Center
Marlene & Stewart Greenebaum Cancer Center

more...

Meeting Announcements

2015 Rally for Medical Research Hill Day
Register now: rallyformedicalresearch.org
September 16-17, 2015
Washington, DC

3rd Annual AACI Physician Clinical Leadership Initiative Meeting
Register now: aaci-cancer.org/pcli_meeting
October 25, 2015
4:00pm-6:00pm EST
Mandarin Oriental, Washington, DC

2015 AACI/CCAF Annual Meeting
Register now: aaci-cancer.org/annual_meeting
October 25-27, 2015
Mandarin Oriental, Washington, DC

2016 Capitol Hill Day
AACI will co-host its annual Capitol Hill Day with the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).
May 11-12, 2016
Washington, DC